COMP <GO>
ALKS vs UNH // RSI-14 & 200D SMA MOMENTUM
Alkermes plc (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: ALKS 6
— UNH 8
▲ RSI-14 & 200D SMA MOMENTUM LEADER: ALKS
LAST: $45.34 (-0.07%) • MKT CAP: $7.61B
rsi-technicals
61.1
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
rsi-technicals
56.0
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALKS VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ALKS | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 86.70% | 88.57% | -1.87 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 14.00% | 11.47% | +2.53 | ALKS | /roic <GO> |
| EV/EBITDA & P/E Valuation | 25.1x | 16.4x | +8.65 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 6.31% | 6.48% | -0.17 | UNH | /fcf-yield <GO> |
| Operating Margin | 17.20% | 4.82% | +12.38 | ALKS | /operating-margins <GO> |
| Net Profit Margin | 16.40% | 3.14% | +13.26 | ALKS | /net-margins <GO> |
| Revenue Growth (YoY) | -5.20% | 6.46% | -11.66 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.03 | 3.12 | +4.91 | ALKS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 6.74% | +0.36 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 61.1 | 56.0 | +5.08 | ALKS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 0.33 | +0.72 | ALKS | /macro-sensitivity <GO> |
| Forward P/E Multiple | 29.3x | 17.1x | +12.21 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.61B | $364.66B | -$357.05B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ALKS REV | UNH REV | ALKS GROSS % | UNH GROSS % | ALKS FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.48B | $447.57B | 86.7% | 88.7% | $480.3M | $16.07B |
| FY 2024 | $1.56B | $400.28B | 84.2% | 88.3% | $405.6M | $20.70B |
| FY 2023 | $1.66B | $371.62B | 44.0% | 89.6% | $326.5M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALKS // BETA 1.05
UNH // BETA 0.33